Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Atea Pharmaceuticals Inc (AVIR)

Atea Pharmaceuticals Inc (AVIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 281,262
  • Shares Outstanding, K 84,463
  • Annual Sales, $ 0 K
  • Annual Income, $ -135,960 K
  • EBIT $ -201 M
  • EBITDA $ -216 M
  • 60-Month Beta 0.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.61

Options Overview Details

View History
  • Implied Volatility 147.71% ( -3.63%)
  • Historical Volatility 49.64%
  • IV Percentile 70%
  • IV Rank 28.46%
  • IV High 491.83% on 10/22/24
  • IV Low 10.80% on 08/26/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 13
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.99
  • Today's Open Interest 1,783
  • Open Int (30-Day) 1,771

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.35
  • Number of Estimates 3
  • High Estimate -0.30
  • Low Estimate -0.38
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +25.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.75 +22.00%
on 12/10/24
3.54 -5.23%
on 12/02/24
-0.07 (-1.90%)
since 11/29/24
3-Month
2.75 +22.00%
on 12/10/24
3.86 -13.08%
on 10/21/24
+0.01 (+0.15%)
since 09/30/24
52-Week
2.75 +22.00%
on 12/10/24
4.60 -27.07%
on 02/29/24
+0.31 (+10.00%)
since 12/29/23

Most Recent Stories

More News
Atea Pharmaceuticals Engages Evercore to Explore Strategic Partnerships for HCV Program

Atea Pharmaceuticals is exploring strategic partnerships to enhance shareholder value related to its hepatitis C treatment program.Quiver AI SummaryAtea Pharmaceuticals, Inc. has announced the engagement...

AVIR : 3.35 (+0.60%)
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

AVIR : 3.35 (+0.60%)
Atea Pharmaceuticals Reports 98% Sustained Virologic Response in Phase 2 Study of Hepatitis C Treatment, Plans Phase 3 Program for 2025

Atea Pharmaceuticals reports 98% sustained virologic response in Phase 2 HCV study; Phase 3 trials expected to begin in 2025.Quiver AI SummaryAtea Pharmaceuticals announced the successful results of its...

AVIR : 3.35 (+0.60%)
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

AVIR : 3.35 (+0.60%)
Atea Pharmaceuticals CEO to Present Business Update at Evercore HealthCONx Conference on December 4, 2024

Atea Pharmaceuticals will present a business update at the Evercore HealthCONx Conference on December 4, 2024.Quiver AI SummaryAtea Pharmaceuticals, Inc. announced that its CEO, Jean-Pierre Sommadossi,...

AVIR : 3.35 (+0.60%)
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

AVIR : 3.35 (+0.60%)
Atea Pharmaceuticals Presents Promising Phase 2 Data on Bemnifosbuvir and Ruzasvir Combination for Hepatitis C at The Liver Meeting 2024

Atea Pharmaceuticals presents Phase 2 data on bemnifosbuvir and ruzasvir as potential hepatitis C treatments at AASLD 2024.Quiver AI SummaryAtea Pharmaceuticals, Inc. has presented three poster presentations...

AVIR : 3.35 (+0.60%)
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

AVIR : 3.35 (+0.60%)
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

AVIR : 3.35 (+0.60%)
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share...

FOLD : 9.45 (-1.87%)
AVIR : 3.35 (+0.60%)
CRSP : 38.75 (-3.17%)
APLS : 32.13 (-1.68%)

Business Summary

Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 3.51
2nd Resistance Point 3.44
1st Resistance Point 3.38
Last Price 3.35
1st Support Level 3.25
2nd Support Level 3.18
3rd Support Level 3.12

See More

52-Week High 4.60
Fibonacci 61.8% 3.89
Fibonacci 50% 3.67
Fibonacci 38.2% 3.46
Last Price 3.35
52-Week Low 2.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar